Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
![Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira[®] in Moderate-to-Severe Psoriasis Patients](/_up/ucb_com_presscenter/images/presscenter_teaser_19.jpg?300)
Twitter Feed
-
At UCB, we have developed a deep understanding of the patient journey in psoriasis and we're working to create differentiated solutions for these patients every day. #EADVVirtual For more: https://t.co/3qkUVIgK8g https://t.co/QmAdkVgyH2
— UCB News (@ucb_news) 31.10.2020 -
Congratulations to our S&TS Devices, Packaging & Wearables Technologies team whose innovation in device technology has earned UCB the 2020 Drug Delivery Innovation Award from @PDAOnline Read more here: https://t.co/M8i2kWxa8j https://t.co/dKpHew
— UCB News (@ucb_news) 29.10.2020 -
For more than a decade, October 29th has served as an opportunity for the advocacy community to shine a spotlight on the impact #psoriasis and #psoriaticarthritis have on individuals globally. Thank you @IFPA for leading these efforts! #WorldPsoriasisDay
— UCB News (@ucb_news) 28.10.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
